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ABSTRACT 
Objective: Purpose of the study to design and formulate Diclofenac sodium (DIC) microsponges. 
Methods: With varied polymer: drug ratio DIC loaded microsponges were prepared with Eudragit RS100 polymer by quasi solvent diffusion 
method. Microsponges evaluated for particle size, entrapment efficiency, drug content, in vitro drug release, Fourier Transform Infrared 
Spectroscopy (FTIR), Differential scanning calorimetry (DSC) and Scanning electron microscopy (SEM). DIC loaded microsponges incorporated into 
ocular in situ gel to attained controlled release by microsponge and improved residence time by gelling system. Ocular in situ gel evaluated for pH, 
drug content determination, gelling capacity, in vitro drug release and sterility study. 
Results: DSER4 microsponge formulation having polymer to drug ratio 1:7 showed satisfactory production yield (68.13%), entrapment efficiency 
(62.86%), drug content (80.73%), requisite particle size (less than 10 µm) (7.52 µm) and in vitro release 87.94% after 6 h. Selected DSER4 
formulation was incorporate into in situ gel. Carbopol 940 forms stiff gel at higher pH so used as a gelling agent, whereas Hydroxypropyl 
Methylcellulose E4M was used as a viscosity-enhancing agent for the formulation of in situ gel in varied compositions. In situ gel formulation IG4 
showed sustained release of 76.92% till the end of 8 h and satisfactory gelling capacity so IG4 further evaluated for sterility test. Rheological studies 
reveal the sol-gel transition of in situ gel occur at the physiological condition to form stiff gel.  
Conclusion: Prepared in situ gel formulations showed sustained drug release for a period of 8 h, which is satisfactory for management of ocular pain. 
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Microsponges are polymeric particulate delivery systems having 5 
to 300 μm diameter with a porous spherical structure formed with 
polymer enclosing active drug ingredients and thereby control drugs 
release [1]. Microsponges are drug-contained polymeric sponge-like 
structures with large porous surface and non-collapsible structure 
made through numerous of interconnecting voids. Microsponges 
display good stability for extreme acidic (pH 1) to extreme basic (pH 
11) conditions also stable at high temperatures (up to 130 °C). This 
entrapment technologies offer high drug payload than others [2].  
INTRODUCTION 
Several different research works of microsponges explored on 
various areas like colonic delivery [3-5], topical delivery [6, 7], 
gastroretentive delivery [8] and percutaneous delivery [9] for 
controlled and sustained drug release. Fewer attempts have been 
made for ophthalmic drug delivery [10-12] of microsponges.  
Ophthalmic drug delivery systems have the main problem of fast and 
substantial precorneal loss, caused by high turnover of tear fluid and 
further draining of tear fluid form eye [13]. Particulate system 
suffers from this nasolacrimal drainage. This possibility of short 
residence time 
In situ gels, upon installation in ocular cul-de-sac, go through a sol-
gel phase transition to form a stiff gel. Phase transition occurs from 
droppable low viscous solution to stiff gel by the influence of 
physicochemical changes i.e. pH, temperature and ions composition, 
caused by tear fluid. This system allows administration of accurate 
doses in the form of drop and augmented residence time which in 
turn improves bioavailability at ocular area [16].  
is eliminated by the incorporation of particulate 
system in situ gel and increases its retention in eye. A lot of attempts 
have been made on the incorporation of particulate system in ocular 
in situ gel [14, 15]. But lesser studies are carried out on 
microsponge-loaded ocular in situ gel.  
Carbopol is a polyacrylic acid (PAA) polymer, which go through a sol to 
gel conversion in an aqueous solution with a change in pH above its pKa 
of about 5.5. However, the high amount of carbopol required to get stiff 
gel results in highly acidic solutions. Such acidic polymeric solution is 
unable to neutralize with the buffering capacity of the tear fluid. So to 
good gelling capacity could be achieved with no further increment in the 
amount of carbopol in polymer solution; by adding HPMC polymer as 
viscosity enhancing polymer [17]. HPMC E4M was selected for in situ gel 
formulation as its frequent use in ophthalmic drug delivery, reliability, 
superior transparency and less incompatibility [18]. 
Diclofenac sodium is effectively used for pain management in cases 
of corneal epithelial defects followed by surgery or accidental 
trauma, and prevention of intraoperative miosis during cataract 
surgery, treatment of postoperative ocular inflammations, chronic 
non-infectious inflammations and for symptomatic relief of seasonal 
allergic conjunctivitis [19].  
The purpose of this study is to attain controlled release through 
microsponge and improve its residence time by incorporating 
microsponges in in situ gel. Eudragit RS100 is used as a polymer for 
the preparation of microsponges. Further microsponges were added 
to HPMC E4M and carbopol in situ gel.  
MATERIALS AND METHODS 
Materials 
Diclofenac Sodium (DIC) was gifted by Nulife Pharmaceuticals, Pune, 
India. Eudragit RS 100 (ERS) and Hydroxypropyl Methylcellulose E4M 
(HPMC E4M) was gifted from Evonik India Pvt. Ltd., Mumbai and 
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Colorcon Asia Pvt. Lmt., Goa, India respectively. Carbopol 940, 
Dichloromethane (DMC), Triethylcitrate, Polyvinylalcohol 30,000–
70,000 (PVA) were procured from Research lab fine chem. Industries, 
Mumbai. All other chemicals used for analysis were analytical grade. 
Preparation of DIC loaded microsponges 
For the preparation of DIC-loaded microsponges with ERS polymer; the 
quasi-emulsion solvent diffusion method was considered. To prepare 
internal phase ERS polymer and triethylcitrate (1% w/v) dissolved in 
dichloromethane. To the prepared solution of polymer, DIC was added 
and homogenously dispersed by ultrasonication to achieve particle size 
reduction. Polymer: drug ratio was varied as 1:1 to 1:13. The internal 
phase was added dropwise to 100 ml of 1% w/v PVA solution. This 
emulsion was stirred for 4hr using magnetic stirrer at 1000 rpm. The 
DIC loaded microsponges were filtered, washed with double distilled 
water and then dried for 48 h at room temperature. DIC-loaded 
microsponges stored for further characterization [5, 20]. 
Characterization of DIC loaded microsponge  
Determination of Percentage Yield 
The percentage yield of obtained microsponges was determined by 
calculating the percentage of the weight of the DIC loaded 
microsponges and the collective weight of DIC and ERS polymer. 
Production yield =  WPr
WTh 




 = Practical mass of DIC loaded microsponges  
Th
Drug content  
 = Theoretical mass (Total weight of DIC and ERS polymer added 
to formulation)  
DIC-loaded microsponge formulation equivalent to 10 mg of DIC of 
each batch was finely crushed in a glass mortar. Further to this add 
60 ml of phosphate buffer (pH 7.4) and the solution was shaken for 4 
h. to dissolve DIC and, filtered. Filtered solution was diluted to 100 
ml with 7.4 phosphate buffer. The resultant solution was analyzed 
on UV spectrophotometer (Jasco V-530) at 275.5 nm. The DIC 
content of the microsponges (DAt
Entrapment Efficiency (%) 
) was calculated.  
Entrapment Efficiency (%) of DIC contained microsponge was 
calculated with an equation, 
Entrapment Efficiency (%) = DAt
DTH




 = Actual drug content in Dried microsponges 
Th
Particle size  
 = Practical drug content (Weight of DIC added in microsponges) 
Optical microscopy was used to measure particle size of 
microsponge by using digital microscope (Motic CV5-2), calibrated 
with ocular micrometer (AmScope MR400 Microscope calibration 
slide). Selected microsponge formulation was dispersed in water 
and few drops were placed on a glass slide. The drop of dispersion 
was observed under a digital microscope. The mean of particle size 
for 300 particles was calculated [21].  
In vitro drug release from DIC loaded microsponges 
Franz diffusion cell was used to carry out in vitro drug release of 
DIC-loaded microsponges. Freshly prepared STF of pH 7.4 was filled 
in the receptor compartment of the Franz diffusion cell and with a 
small magnetic bar STF was constantly stirred at 100 rpm. A dialysis 
membrane (12 000–14 000 Dalton MW, Hi-media, India) soaked for 
12 h in the STF and stretched in between donor and receptor 
chambers. DIC loaded microsponge dispersed in distilled water and 
placed in donor compartment; and covered with a coverslip. 
Samples each of 1 ml, were withdrawn for at predetermined time 
intervals from the receptor chambers and replaced with fresh STF 
and sink conditions. In vitro drug release was performed thrice for 
each formulation; further samples were analyzed by measuring the 
absorbance at 275.5 nm using UV spectrophotometer [22].  
In vitro drug release kinetic study of DIC loaded microsponges 
Drug Kinetic model studies of in vitro release data of microsponge 
formulations were performed to conclude the DIC release 
mechanism. In vitro release data was fitted to the following models 
and regression coefficient values (r2
• Zero-order kinetic model (d
) were calculated. 
0
• First order kinetic model (log d = log d
–d = Kt) 
0
• Hixson-crowell kinetic model (d
–Kt/2.303) 
0 1/3 –d1/3  
• Higuchi kinetic model (d
=Kt)  
0–d = Kt1/2
Where d is the quantity of the DIC remaining in the microsponge at 
time t and d
)  
0  is the initial amount of the DIC in the microsponge. 
Diffusion mechanism was explained by the diffusion exponent (n) 
value of Korsmeyer–Peppas equation (d0–d/d0 = Ktn
Fourier transform infrared spectroscopy (FTIR) 
). The diffusion 
exponent value n<0.45 signifies the release follows fickian 
mechanism. If exponent value indicates 0.5<n<0.8 signifies the 
release follows the non-fickian mechanism [23]. 
FTIR spectra of DIC, physical mixture of DIC and ERS polymer and; 
selected microsponge formulations were recorded in ATR mode 
with a Perkin Elmer (Model: SPECTRUM BX). 
Differential scanning calorimetry (DSC)  
Thermal analysis of DIC and the selected microsponge were scanned 
at a rate of 20 °C/min on a Differential scanning calorimetry (Mettler 
Toledo, Model: StareSW920, Mumbai) between 40 °C and 320 °C 
under dynamic nitrogen atmosphere DSC studies were carried out 
intend to find out any incompatibility. 
Scanning electron microscopy (SEM) 
A Field Emission Scanning Electron Microscope (FEI Nova NanoSEM 
450) operated at 3.00 kV and magnification of ×500 and ×5000; was 
used to study the morphology of microsponges. Selected 
microsponge need to coat with gold-palladium alloy for 45s under 
an argon atmosphere before observation.  
Formulation of DIC loaded microsponges containing ocular in 
situ gel 
Ocular in situ gel formulations containing varied concentrations of 
Carbopol 940 and HPMC E4M were prepared as per the composition 
summarized in table 1. Accurately weighed HPMC E4M was 
dispersed in 50 ml of distilled water and carbopol 940 was 
dispersed over this solution and kept to hydrate 12h. The solution 
was stirred with an overhead stirrer. DIC-loaded microsponges 
(equivalent to 0.1 gm DIC) were dispersed in distilled water and 
added to the polymeric solution. Benzalkonium chloride was mixed 
to the prepared solution. Required amount of distilled water was 
added to make up the volume to 100 ml. Prepared in situ gel 
formulation thoroughly agitated and sterilized in an autoclave at 
121 °C for 20 min [24, 25]. 
 
Table 1: Composition of DIC loaded microsponge containing ocular in situ gel formulations 
Ingredient (%W/V) IG1 IG2 IG3 IG4 
Carbopol 940  0.1 0.1 0.1 0.1 
HPMC E4M 0.2 0.4 0.6 0.8 
Benzalkonium chloride  0.02  0.02  0.02  0.02  
Distilled water qs  100 100 100 100 
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Characterization of DIC loaded microsponges containing ocular 
in situ gel 
Determination of visual appearance and clarity  
The appearance and clarity ocular in situ gel formulations were 
evaluated by observing gel in front of black and white background in 
fluorescent light inside a bright, lightened cabinet.  
Determination of pH  
The pH of in situ gel formulation was determined using a pH meter 
(Labindia, Mumbai, Model: GMPH) which was calibrated before use 
with the buffered solution at pH 4 and 7. Three readings were taken 
for every sample and the average of three samples was calculated. 
Drug content determination 
In situ gel formulation was added to 100 ml volumetric flask. To this 
add 60 ml of pH 7.4 phosphate buffer was added and shaken for 4 h. 
and filtered. Filtered solution was further diluted to 100 ml with 7.4 
phosphate buffer. Analyzed using UV spectrophotometer (UV1Jasco, 
Japan, Model: V-530) with phosphate buffer (pH 7.4) as blank. The 
drug content of the microsponges was calculated. 
Determination of gelling capacity  
To vial containing 2 ml of freshly prepared STF (maintained at 37 
°C), drop of the in situ gel was added. The drop of in situ gel was 
observed and the time taken by drop for gelation was noted also the 
time taken for the gel formed to dissolve was noted [12]. Gelling 
capacity of formed in situ gel was noted as follows. 
( ̶) No gel formation 
(+)  The gel formation occur after few minutes and dissolves 
quickly 
(++)  Instantaneous gel formation and resides for few hours  
(+++) Instantaneous stiff gel formation which resides for long 
period of time 
Rheological studies 
Brookfield digital viscometer (DVII+PRO) was used to measure the 
viscosity (in cps) of the prepared in situ gel formulations. The 
spindle (T-D) was rotated at 20 rpm. Three readings were reported 
30 sec after putting the motor on and an average calculated. 
In vitro drug release from In situ ocular gel containing DIC 
loaded microsponges  
The in vitro drug release from the in situ ocular gel was carried out 
as per procedure described above under ‘In vitro drug release from 
DIC loaded microsponges’. The in situ ocular gel was placed on donor 
compartment. To the top of the in situ gel 250 μl of the STF was 
added to simulate the small amount of tear secreted on the eye 
surface and covered with a coverslip. 1 ml of samples were taken out 
at time intervals 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 h with timely 
maintenance of sink condition. Samples were analyzed by using UV 
spectrophotometer [22]. In vitro drug release studies performed 
thrice for each in situ gel formulation. 
In vitro drug release kinetic study of in situ ocular gel 
containing DIC loaded microsponges 
Kinetic study of drug release data was performed ocular in situ gel as 
described above under ‘In vitro drug release kinetic study of DIC 
loaded microsponges’. 
Sterility study  
The sterility study was performed according to Indian 
Pharmacopoeia [26]. In situ ocular gel formulation was directly 
inoculated aseptically into fluid thioglycolate medium (20 ml), and 
incubated for 14 d at 30 °C to 35 °C. Separately, In situ ocular gel 
formulation was directly inoculated aseptically into soyabean-casein 
digest medium (20 ml) and incubated for 14 d 20 °C to 25 °C. 
Microbial contamination was tested with a Fluid thioglycollate 
medium and the presence of fungi tested with soybean-casein digest 
medium with incubation under aerobic conditions. The tests were 
performed in triplicate under aseptic conditions to avoid accidental 
contamination. The positive and negative controls were performed 
for the examination of growth promotion and sterility, respectively.  
RESULTS  
Characterization DIC loaded microsponge formulations  
Production yield (%), drug content (%) and entrapment 
efficiency (%) 
With increase in polymer: drug ratio there is increment in 
production yield, drug content and entrapment efficiency. 
Production yield varied between 27.50% and 72.50%. At low DIC 
concentration production yield was found extremely low (27.50%). 
Drug content varied from 27.27% to 90.15% (table 2). 
Particle size analysis 
Particle size is an important parameter in ocular administration of 
particular system. Particle size range from 20.39±4.21 µm and 
0.78±0.11 µm. Particle size decreased as an increase in Polymer: 
drug ratio. This finding is in accordance with literature [2]. 
In vitro drug release of DIC loaded microsponges 
In vitro drug release is graphically presented in fig. 1. Formulation 
DERS4 (87.94%) and DERS5 (90.73%) showed relatively comparable 
drug release as compared to DERS3 (79.41%) at the end of 6 h. Study 
revealed that the highest cumulative drug release after 6 h is 90.73%. 
Kinetic analysis of the in vitro release data of DIC loaded 
microsponge formulations  
The release of DIC in both DIC-loaded microsponges formulations 
DERS3 and DERS4 showed more adherence to Higuchi’s diffusion 
kinetic model, with regression coefficient (r2
 
)value 0.9730 and 
0.9655, respectively (table 3). 
 
Fig. 1: In vitro release profiles of DIC loaded microsponge formulations (DERS3, DERS4 and DERS5). The data is expressed as mean±SD, n=3  
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Table 2: Characterization data of DIC loaded microsponges 




Particle size (µm) Production yield (%) Drug content (%) Entrapment efficiency (%) 
1 DERS1 1: 1 20.39±4.21 27.50±3.54 27.27±5.43 15.00±3.15 
2 DERS2 1:3 13.14±2.63 43.75±2.51 45.71±4.92 26.67±4.84 
3 DERS3 1: 5 8.32±1.94 57.50±4.13 73.91±3.46 51.00±3.61 
4 DERS4 1:7 7.52±2.29 68.13±3.98 80.73±3.51 62.86±5.49 
5 DERS5 1: 9 6.98±1.45 64.00±4.56 86.72±1.36 61.67±2.27 
6 DERS6 1:11 1.64±0.82 68.75±1.32 87.88±2.40 65.91±3.65 
7 DERS7 1: 13 0.78±0.11 72.50±2.12 90.15±4.22 70.38±1.74 
*n=3, mean±SD 
 













DSER3 0.9271 0.9602 0.9730 0.9625 0.67 
DSER4 0.9139 0.9301 0.9655 0.9483 0.67 
DSER5 0.9373 0.9883 0.9772 0.9861 0.72 
 
DERS5 followed first-order drug release kinetic, with regression 
coefficient (r2
Microsponge formulation DERS4 was selected as having requisite 
particle size, sustained release and satisfactory Production yield, 
Entrapment efficiency and Drug content. DERS4 was further studied 
for FTIR, DSC and SEM. 
) value 0.9883. The diffusion exponents (n) of all 
microsponge formulations have a value more than 0.5 but less than 
0.8. This indicates that the DIC release mechanism from 
microsponges is non-Fickian diffusion.  
Fourier transform infrared spectroscopy (FTIR) 
Drug-polymer compatibility in the selected microsponges DERS4 was 
evaluated by FTIR. The principle IR peaks of DIC appeared at 
wavenumbers of 3361.34 cm–1 (NH starching of secondary amine 
groups), 1302.12 cm–1 (C-N stretching), 1503.46 cm–1 (C=C ring 
stretching) and 1548.76 cm–1 (C=O stretching of the carboxyl ion) and 
757.12 cm–1
 
 (C-Cl stretching) [27]. The characteristic DIC peaks were 
present in the physical mixture as well as in the DIC-loaded microsponges 
DERS4 (fig. 2) with no significant changes in frequencies. 
 
Fig. 2: FTIR spectrum of (a) DIC (b) Physical mixture of DIC and ERS polymer (c) Selected microsponge formulation DERS4 
 
 
Fig. 3 DSC thermogram of (a) Pure DIC and (b) Selected microsponge DERS4 
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Differential scanning calorimetry (DSC) 
The thermal behavior of the DIC, and selected microsponge DERS4 
are presented in (fig. 3). 
DSC thermogram of DIC exhibited endothermic peaks, initial peak 
due to loss of water followed by the other sharp endothermic peak 
at 291.97 °C, indicating to melting point of DIC in crystalline form; 
reflecting DIC purity [9]. The DSC curves of DERS4 formulation 
exhibited suppressed peak of the DIC at 280.40 °C. 
Scanning electron microscopy (SEM) 
Morphology DIC loaded microsponges were studied by SEM analysis. 
The representative SEM images of microsponge (DERS4) are shown 
in (fig. 4 and 5). 
Formulation and characterization of in situ ocular gel 
containing DIC loaded Microsponges  
In situ ocular gel found clear with suspended microsponge particles. 
The pH of in situ gel solution was found in range 6.03 to 6.13.  
The formulation have an optimum viscosity at Non-Physiological 
conditions that will give ease in instillation to eye in the form of drop, 
which go through a quick sol to gel transition (triggered by pH) at 
physiological conditions (37 °C and 7.4 pH) as shown in table 4. 
The in vitro drug release from in situ ocular gel showed sustained 
release. The % cumulative drug release from formulations was 
found to be IG1 (89.25%), IG2 (84.23%), IG3 (76.92%), and IG4 
(69.64%) after 8 h as shown in fig. 6. 
The drug release kinetic of all in situ gel formulations suggests 
Higuchi kinetic model (table 5) and diffusion exponent showed non-
fickian diffusion mechanism. 
 




Fig. 5: SEM of selected microsponge DERS4 (Magnification x 
5000)
 
Table 4: Characterization of DIC loaded microsponge containing ocular in situ gel 
Formulation code IG1 IG2 IG3 IG4 
Gelling capacity + ++ ++ +++ 
pH 6.04 6.03 6.13 6.10 
Viscosity 
(cP) 
At Non-Physiological conditions  860±120 1008±142 1843±176 2308±241 
At Physiological conditions (pH 7.4 and 37 °C) 1852±194 4340±241 6651±186 7035±108 
Drug content (%) 86.54±1.74 90.73±1.40 94.26±1.61 89.83±2.24 
 *n=3, mean±SD 
 
 
Fig. 6: In vitro release profiles of DIC loaded microsponge containing ocular in situ gel. The data is expressed as mean±SD, n=3 
 
Table 5: Release kinetics study of DIC loaded microsponge containing ocular in situ gel 
Formulation 
code 
Zero order model 
(r2








IG1 0.9536 0.9755 0.9900 0.9880 0.68 
IG2 0.9536 0.9884 0.9936 0.9904 0.68 
IG3 0.9260 0.9904 0.9941 0.9753 0.69 
IG4 0.9410 0.9877 0.9931 0.9763 0.68 
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Sterility study 
The study results of the sterility study are summarized in table 6, the 
prepared ocular in situ gel formulation passed the sterility test. 
There was zero growth found in fluid thioglycollate medium and 
soyabean casein digest medium. 
 
Table 6: Sterility test of ocular in situ gel formulation IG3 
Organism Bacteria Fungi  
+ve Control Turbid Turbid 
-ve Control Clear Clear 
IG3 Clear Clear 
 *n=3, mean±SD 
 
DISCUSSION 
DIC-loaded microsponges were prepared by the quasi emulsion 
solvent diffusion method using ERS polymer. In literature, this 
method is considered to be simple, replicable, rapid and solvent 
toxicity also got eliminated [3]. With the increase in drug 
concentration in polymer: drug ratio; production yield, drug content 
and entrapment efficiency increases. As more drug are available for 
entrapment leading to high amount of drugs in microsponges 
leading to increased values of production yield, drug content and 
entrapment efficiency. The lower values of entrapment efficiency 
(15.00%) could be due to dissolution of some fraction of DIC in PVA 
solution during the emulsification process [20]. With an increase in 
level of DIC (besides drug dissolution), more drugs available for 
entrapment in ERS polymer matrix. As a result entrapment 
efficiency increases with increment in polymer: drug ratio. 
High PVA concentration and high stirring speed yield small particle 
size which is requisite for this study. In the quasi emulsion solvent 
diffusion method, organic phase i.e. dichloromethane diffuses out to 
yield particles in which drug particle surrounded by polymer. At 
high polymer: drug ratio less polymer amounts surrounds the drug 
causing decreased particle sizes of microsponges [2].  
As in the polymer: drug ratio the concentration of drug increased, 
polymer units surrounding drug units is less than at low. During 
phase transition process less polymer got bound to the drug giving 
smaller size microsponge. Particle size of less than 10 µm is required 
for ocular administration [11]. Hence microsponge formulations 
above 10 µm were not further investigated. Microsponges have 
particle size range from 5-300 μm. So microsponges below 5 μm 
were also excluded from further studies. 
Sustained release of drug was as a result of incorporation of drug in 
polymer Matrix [28]. Drug release is inversely related to the 
Polymer: drug ratio. High Polymer: drug ratio yield smaller particles 
having more active surface area which coming in contact with 
diffusion media. Also smaller particle exhibit shorter path length 
drug need to travel through microsponge pores into the diffusion 
media [8]. Drug release rates were increased with an increasing 
amount of DIC in microsponge. At a high Polymer: drug ratio, the 
corresponding polymer amount is lesser. As more drug got released 
more void channels formed which allows more diffusion media to 
enter and in turn increases release rate.  
FTIR studies confirms that no interaction between drug and ERS 
polymer. The thermogram of microsponge formulation showed 
suppressed peak signify uniform dispersion of DIC in polymeric 
matrix and altered crystallinity of DIC. Absence of any other 
significant endothermic peak, in the melting point range of DIC 
(melting point found as 286.26 °C) indicates that absence of any 
interaction between the DIC and ERS polymer, and verify the 
aptness of microsponge preparation technique [27].  
SEM results indicated that DERS4 microsponges were tiny, porous 
and spherical. Surface integrity of microsponge got retained. 
Microsponges particles are free from aggregates. This might be due 
to aqueous solution of PVA which is used during the quasi emulsion 
solvent diffusion method. PVA reduces surface charge on the particle 
giving aggregate free microsponges [29].  
In the present investigation, incorporation of DIC-loaded ERS 
polymeric microsponges was performed into in situ gel formulated 
using polymers Carbopol 940 and HPMC E4M. Carbopol 940 and 
HPMC E4M were used in combination as alone high concentration of 
carbopol 940 yield a highly acidic solution, which is not suitable for 
ocular administration (pH of lacrimal fluid 7.4) [30]. So moderate 
concentration of Carbopol 940 (0.1% w/v) along with viscosity-
enhancing polymer HPMC E4M (0.2-0.8 % w/v) [31] was used to 
formulate in situ gel. The pH of formulation would raises instantly to 
pH 7.4 (an ideal ocular pH) after instillation into eye due to pH of 
lacrimal secretion. Thus, the formulations were considered to be 
suitable for ocular administration and may not cause any irritation 
to ocular tissues upon instillation [25].  
At Physiological conditions formulation form stiff gel which increases 
residence time of microsponges incorporated in gel. In situ gel 
formulation contains HPMC E4M and carbopol 940 which are known 
to gel reversibly on elevation of temperature and pH respectively [31]. 
Hence at physiological conditions viscosity of formulation increases to 
form a stiff gel, as both pH and temperature increases. 
Formed stiff gel should display good integrity and not to get dissolve 
and erode for extended period of time. Formulations IG2 and IG3 
exhibited satisfactory “++” grade of gelling capacity [12].  
In situ gel formulation IG3 showed sustained release with a 
satisfactory “++” grade of gelling capacity. Hence, IG3 formulation 
was taken for further Sterility test. Sterility study results proved the 
efficiency of autoclaving for sterilization of ocular in situ gel. 
CONCLUSION 
With the present study, the potential of DIC loaded microsponges as 
drug carriers for ocular delivery was investigated. Microsponges 
showed good practical yield, entrapment efficiency, drug content 
and suitable particle size for ocular administration. Controlled 
release of up to 6 h observed through DIC loaded microsponges. DIC 
loaded microsponges successfully incorporated in in situ gels. The 
clarity, pH, drug content, gelling capacity and rheological studies of 
DIC loaded microsponges containing ocular in situ gel formulations 
were found to be acceptable. Further, in situ gel formulations 
showed sustained drug release for a period of 8 h, which is 
satisfactory for management of ocular pain.  
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